Lanean...
Nivolumab-associated acute glomerulonephritis: a case report and literature review
BACKGROUND: Immune checkpoint inhibitors are changing the landscape of oncology treatment as they are significantly improving treatment for multiple malignancies. Nivolumab, an anti-programmed death 1 antibody, is a US Food and Drug Administration-approved treatment for melanoma, non-small cell lung...
Gorde:
| Argitaratua izan da: | BMC Nephrol |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5120473/ https://ncbi.nlm.nih.gov/pubmed/27876011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-016-0408-2 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|